Talha Badar, Hematology/Oncology Specialist at Mayo Clinic, shared a post on X:
“VICEROY open label phase1/2 dose-ranging/ expansion study with Ven 200 mg and Ven 400 with AZA 7 days/ Gilt 28 days with FLT3m AML. Presented by Dr. Jessica Altman
Summary
Data presented showed cCR ~90% in both gps with comparable OS.
VEN duration was shorter then planned 28 days; median 16 and 10 days in C1 and C3.”
More from Talha Badar.